Steven L. Basta - 10 Feb 2026 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Reporting relationship: President and CEO, Director
Issuer ticker: PHAT
Reported as of: 10 Feb 2026
Net transaction value: -$80,471
SEC form: 4
Accepted by SEC: 12 Feb 2026, 16:34:07 UTC
Prior SEC filing: 02 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Steven L. Basta

Key filing fact

Steven L. Basta filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 12 Feb 2026.

Key facts

This page summarizes Steven L. Basta's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2026, 16:34.

Change

Previous filing in this sequence was filed on 02 Jan 2026.
Current net transaction value: -$80,471.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001417397 Primary reporting owner

Basta Steven L

Relationship: President and CEO, Director
Address: C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK
Signature: /s/ Steven L. Basta
Signature date: 12 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHAT transaction

Common Stock

Award

Transaction value: $0
Shares: +12,362
Change %: +3.4%
Price: $0.000000
Shares after: 379,592
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F1, F2

PHAT transaction

Common Stock

Tax liability

Transaction value: $80,471
Shares: -6,277
Change %: -1.7%
Price: $12.82
Shares after: 373,315
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026.

Footnote F2

Includes 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026.

Footnote F3

Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.